Business
TME Pharma Announces New Strategy
BERLIN, May 05, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today a strategic change to facilitate ongoing efforts to finance the next clinical trial for NOX-A12 through agreements with pharma or financial partners.
About this update from Tme Pharma N.v.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":313,"url":"https://media.zenfs.com/en/business-wire.com/31ee0f3f8c118afe59e2fa29a99882f5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Cf8iZOdPacFJDRvUMCZUlw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/31ee0f3f8c118afe59e2fa29a99882f5","width":960,"height":300},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/nKF869YiGQL2QfgXdTWdzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD02MjY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/31ee0f3f8c118afe59e2fa29a99882f5","width":1000,"height":313}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Diede van den Ouden, an experienced CEO with successful background in small-cap turnarounds, to be nominated for appointment as CEO at upcoming AGM in June 2025","length":160,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Operational costs to be strongly reduced through outsourced staffing model as from July 1, 2025 while maintaining the ability to advance both NOX-A12 and NOX-E36 assets","length":168,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Streamlined Supervisory Board with two members stepping down at upcoming AGM","length":76,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Management confident in securing non-dilutive financing to cover short-term operational needs","length":93,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Support for the new strategy and CEO nomination from existing shareholders with significant shareholdings","length":105,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":602,"olType":false},{"type":"text","content":"BERLIN, May 05, 2025--(BUSINESS WIRE)--Regulatory News:","length":55,"tagName":"p"},{"type":"text","content":"TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today a strategic change to facilitate ongoing efforts to finance the next clinical trial for NOX-A12 through agreements with pharma or financial partners.","length":361,"tagName":"p"},{"type":"text","content":"The strategy wi...